Posted by Michael Wonder on 24 Sep 2024
Lantern Pharma announces three US FDA rare paediatric disease designations granted to LP-184 in multiple ultra rare children’s cancers
23 September 2024 - Lantern Pharma announced today that the company has been granted three rare paediatric disease designations by the FDA.
Lantern was granted these rare paediatric disease designations in: malignant rhabdoid tumours, rhabdomyosarcoma and hepatoblastoma.
